Research Study

A Multicentre, Phase 2 Clinical Trial to Establish the Efficacy and Safety of Repeat Dosing of Autologous Endothelial Progenitor Cells (EPCs) Transfected With Human Endothelial NO-synthase (eNOS) in Patients With Pulmonary Arterial Hypertension (PAH) on Top of Conventional Treatments
Principal Investigator 
John Swiston

Overview

Body Locations and Systems 
Pulmonary Hypertension
ClinicalTrials.gov# 
NCT03001414
Status 
Recruiting
Study Start/End 
Jan 14, 2019 to Apr 30, 2021
Locations 
Diamond Health Care Centre, Vancouver General Hospital
Name/Title 
Mami Okada, Research Coordinator
Phone 
604-875-4111 ext.69831
Email Address 
mami.okada@vch.ca
Purpose of Study 

The purpose of this study is to establish the efficacy and safety of repeated monthly dosing of endothelial progenitor cells (EPCs) transfected with human endothelial NO-synthase (eNOS) in patients with symptomatic severe pulmonary arterial hypertension (PAH) on available PAH-targeted medical therapy.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.